Dr Rodriguez was funded by grants from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) (R01HL168188; R01HL167974; R01HL169345), the American Heart Association/Harold Amos Medical Faculty Development program, and the Doris Duke Foundation (Grant #2022051). Dr Sandhu is supported by a grant from the NaHLBI (1K23HL151672-03). Dr Mastrodicasa has consulted for and is a stakeholder of Segmed Inc. Mr Eng and Mr Khandwala are employees of Bunkerhill Health. Dr Chaudhari has received research support from the NIH, GE HealthCare, Philips, Microsoft, Amazon; and has provided consulting services to Elucid Bioimaging, Patient Square Capital, Subtle Medical, and Chondrometrics GmbH. Dr Maron has received research funding from Cleerly; and consultant funding from Regeneron. Dr Rodriguez holds equity from Carta Healthcare and HealthPals; and has received consulting fees from HealthPals, Novartis, NovoNordisk, Esperion Therapeutics, Movano Health, Kento Health, Inclusive Health, Edwards, Arrowhead Pharmaceuticals, HeartFlow, iRhythm, Amgen, and Cleerly Health outside of the submitted work. Dr Sandhu has received research funding from the American Heart Association, the NIH, AstraZeneca, Novo Nordisk, and Novartis Pharmaceuticals; and has consulted for Lexicon Pharmaceuticals and Reprieve Cardiovascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.